Sharon Larkin
Direttore/Membro del Consiglio presso SENSEONICS HOLDINGS, INC.
Patrimonio netto: 125 119 $ in data 30/04/2024
Profilo
Sharon D.
Larkin is currently the Director at Senseonics, Inc. and an Independent Director at Senseonics Holdings, Inc. Previously, she worked at Abbott Laboratories as the Divisional VP-HR & Medical Devices Group from 2011 to 2015.
She also served as the Senior VP-Human Resources & Administration at Assertio Therapeutics, Inc. from 2017 to 2020.
Ms. Larkin completed her undergraduate degree at Georgia Institute of Technology.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/04/2024 | 299 327 ( 0.06% ) | 125 119 $ | 30/04/2024 |
Posizioni attive di Sharon Larkin
| Società | Posizione | Inizio |
|---|---|---|
| SENSEONICS HOLDINGS, INC. | Direttore/Membro del Consiglio | 08/12/2021 |
Senseonics, Inc.
 Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Direttore/Membro del Consiglio | 01/12/2021 |
Precedenti posizioni note di Sharon Larkin
| Società | Posizione | Fine |
|---|---|---|
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Direttore Amministrativo | 01/01/2020 |
| ABBOTT LABORATORIES | Ufficiale delle Risorse Umane | 01/09/2015 |
Formazione di Sharon Larkin
| Georgia Institute of Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| SENSEONICS HOLDINGS, INC. | Electronic Technology |
| Aziende private | 2 |
|---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Senseonics, Inc.
Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Electronic Technology |
- Borsa valori
- Insiders
- Sharon Larkin
